Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA:688336)

Market Cap	37.01B
Revenue (ttm)	1.24B
Net Income (ttm)	716.42M
Shares Out	616.79M
EPS (ttm)	1.16
PE Ratio	51.72
Forward PE	120.80
Dividend	0.12 (0.20%)
Ex-Dividend Date	Jun 13, 2025

Volume	9,318,771
Average Volume	14,158,738
Open	59.00
Previous Close	60.00
Day's Range	56.60 - 60.88
52-Week Range	15.22 - 68.68
Beta	0.72
RSI	61.46
Earnings Date	Aug 22, 2025

About SHA:688336

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of antibody drugs in China. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an injection; and Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation. These products are also used in conjunction w...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 995
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688336

Financial Performance

In 2024, SHA:688336's revenue was 1.19 billion, an increase of 17.70% compared to the previous year's 1.01 billion. Earnings were 704.58 million, an increase of 139.15%.